Some recent randomized trials showed no significant association of PD-L1 with clinical response to anti-PD-1/PD-L1 monotherapy and anti-PD-1/PD-L1 plus chemotherapy or chemoradiotherapy in NSCLC (67, 109, 110). The gene discussed is CD274; the disease is non-small cell lung carcinoma.